World's Best Scientists 2026 revealed!
Gordon J. Freeman

Gordon J. Freeman

Award Badge
Best Scientists
2025
Award Badge
Immunology
USA
2026

D-Index & Metrics

Best Scientists

D-Index
196
Citations
162394
World Ranking
341
National Ranking
226

Immunology

D-Index
201
Citations
173278
World Ranking
11
National Ranking
6

Medicine

D-Index
201
Citations
173535
World Ranking
178
National Ranking
118

Gordon J. Freeman publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Gordon J. Freeman sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 618 publications — 95th percentile

95% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Gordon J. Freeman D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Gordon J. Freeman sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 201 D-Index — 100th percentile

100% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Research.com Recognitions

  • 2026 - Research.com Immunology in United States Leader Award
  • 2025 - Research.com Best Scientists Award
  • 2025 - Research.com Immunology in United States Leader Award
  • 2020 - Fellow, National Academy of Inventors
  • 2017 - Warren Alpert Foundation Prize For their collective contributions to the pre-clinical foundation and development of immune checkpoint blockade, a novel form of cancer therapy that has transformed the landscape of cancer treatment.

Overview

Gordon J. Freeman is affiliated with Harvard University in the United States. Their research primarily focuses on the fields of medicine and immunology and microbiology, with significant contributions in immunology, oncology, and molecular biology. Their work also intersects areas such as pulmonary and respiratory medicine and cancer research.

The scientist's main research topics include cancer immunotherapy and biomarkers, immune cell function and interaction, immunotherapy and immune responses, CAR-T cell therapy research, immune cells in cancer, T-cell and B-cell immunology, and renal cell carcinoma treatment.

Gordon J. Freeman has contributed extensively to several publication venues, most notably:

  • Cancer Research
  • Regular and Young Investigator Award Abstracts
  • Clinical Cancer Research
  • Cancer Immunology Research
  • Nature

Frequent coauthors collaborating with Freeman include:

  • Arlene H. Sharpe
  • Toni K. Choueiri
  • Sabina Signoretti
  • David F. McDermott
  • Catherine J. Wu

Selected recent papers authored or coauthored by Freeman are as follows:

  • Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma, 2020, Nature Medicine
  • The importance of exosomal PDL1 in tumour immune evasion, 2020, Nature Reviews Immunology
  • Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis, 2021, Cell
  • Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy, 2020, Nature Cell Biology
  • Tumor cells dictate anti-tumor immune responses by altering pyruvate utilization and succinate signaling in CD8+ T cells, 2022, Cell Metabolism

Freeman's contributions have been recognized with awards such as the Fellow of the National Academy of Inventors in 2020 and the Warren Alpert Foundation Prize in 2017, awarded for collective contributions to the development of immune checkpoint blockade as a cancer therapy.

Best Publications

  • PD-1 and its ligands in tolerance and immunity

    Mary E. Keir;Manish J. Butte;Gordon J. Freeman;Arlene H. Sharpe

  • Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.

    Gordon J. Freeman;Andrew J. Long;Yoshiko Iwai;Karen Bourque

  • Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response

    Peng Jiang;Shengqing Gu;Deng Pan;Jingxin Fu

  • Restoring function in exhausted CD8 T cells during chronic viral infection.

    Daniel L. Barber;E. John Wherry;David Masopust;Baogong Zhu

  • PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

    Stephen M. Ansell;Alexander M. Lesokhin;Alexander M. Lesokhin;Ivan Borrello;Ahmad Halwani

  • PD-L2 is a second ligand for PD-1 and inhibits T cell activation

    Yvette Latchman;Clive R. Wood;Tatyana Chernova;Divya Chaudhary

  • PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression

    Cheryl L Day;Daniel E Kaufmann;Photini Kiepiela;Julia A Brown

  • THE B7 FAMILY REVISITED

    Rebecca J. Greenwald;Gordon J. Freeman;Arlene H. Sharpe

  • CTLA-4 can function as a negative regulator of T cell activation

    Theresa L. Walunas;Deborah J. Lenschow;Christina Y. Bakker;Peter S. Linsley

  • CD4+CD25high Regulatory Cells in Human Peripheral Blood

    Clare Baecher-Allan;Julia A. Brown;Gordon J. Freeman;David A. Hafler

  • The B7–CD28 superfamily

    Arlene H Sharpe;Gordon J Freeman

  • Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection

    Shawn D Blackburn;Haina Shin;W Nicholas Haining;W Nicholas Haining;Tao Zou

  • PD-L1 regulates the development, maintenance, and function of induced regulatory T cells

    Loise Marie Francisco;Victor H. Salinas;Keturah Elise Brown;Vijay K. Vanguri;Vijay K. Vanguri

  • Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

    Matthew M. Gubin;Xiuli Zhang;Heiko Schuster;Etienne Caron

  • Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses

    Manish J. Butte;Mary E. Keir;Theresa B. Phamduy;Arlene H. Sharpe

  • Defining CD8 + T cells that provide the proliferative burst after PD-1 therapy

    Se Jin Im;Masao Hashimoto;Michael Y Gerner;Michael Y Gerner;Junghwa Lee

  • Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease

    Laurent Monney;Catherine A. Sabatos;Jason L. Gaglia;Akemi Ryu

  • The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection

    Arlene H Sharpe;E John Wherry;Rafi Ahmed;Gordon J Freeman

  • Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.

    Shohei Koyama;Esra A. Akbay;Yvonne Y. Li;Grit S. Herter-Sprie

  • Combination cancer immunotherapy and new immunomodulatory targets.

    Kathleen M. Mahoney;Paul D. Rennert;Gordon J. Freeman

  • Tissue expression of PD-L1 mediates peripheral T cell tolerance

    Mary E. Keir;Spencer C. Liang;Indira Guleria;Yvette E. Latchman

Frequent Co-Authors

Arlene H. Sharpe
Arlene H. Sharpe Harvard University
Lee M. Nadler
Lee M. Nadler Harvard University
Vassiliki A. Boussiotis
Vassiliki A. Boussiotis Beth Israel Deaconess Medical Center
Scott J. Rodig
Scott J. Rodig Harvard University
Rosemarie H. DeKruyff
Rosemarie H. DeKruyff Stanford University
Rafi Ahmed
Rafi Ahmed Emory University
Sabina Signoretti
Sabina Signoretti Brigham and Women's Hospital
John G. Gribben
John G. Gribben Queen Mary University of London
Dale T. Umetsu
Dale T. Umetsu Stanford University
F. Stephen Hodi
F. Stephen Hodi Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a degree in Immunology often leads students to explore complementary healthcare fields, including advanced nursing roles. For those interested in transitioning into specialized nursing, programs like cheapest psych np programs offer cost-effective pathways to become psychiatric nurse practitioners.

For nurses aiming to elevate their qualifications, understanding the financial outlook is crucial. Insights into the doctor of nursing practice salary by state help guide career decisions, balancing educational investments with potential earnings.

Specialization is key in nursing, and many professionals look to advanced acute care roles. Programs designed to support this transition are well-explained in resources outlining acnp programs, enabling family nurse practitioners to become Acute Care Nurse Practitioners.

Additionally, accelerated pathways like accelerated rn to np programs make it possible for registered nurses to fast-track their journey toward becoming nurse practitioners, complementing their background in immunology and healthcare.

Best Scientists Citing Gordon J. Freeman

Trending Scientists

Recently Published Articles